10 costliest claims conditions account for $1.3B from 2013 to 2016

Sun Life has released its fifth annual “Sun Life Stop-Loss Research Report," outlining the top 10 catastrophic claims conditions. The report provides data from 53,000 claimants and $4.5 billion in stop-loss reimbursements to project changes over time in costs of medical conditions.

The study included Sun Life Stop-Loss claims data from over 100,000 employees around the U.S. from 2013 to 2016.

Results included:

  • The top three conditions (malignant neoplasm, leukemia/lymphoma and chronic/end-stages renal disease) accounted for 32.3 percent of total payments.
  • The top 10 medical conditions accounted for 51.7 percent of all catastrophic claims.
  • Cancer remains the costliest illness and continue to increase, accounting for 26.7 percent of all stop-loss claims reimbursements.
  • While kidney disease remained at No. 3, overall average costs are declining.
  • Transplants continue to climb the list, although only moving up one stop to No. 10 in this report. Costs are increasing overall.
  • Million-dollar claimants increased 26 percent from 2012 to 2015.
  • While million-dollar claimants represented 2.2 percent of total claimants, they encompassed 23 percent of all stop-loss claims reimbursements.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year. 

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.